Regeneron Pharmaceuticals, Inc. (REGN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 822.96 |
| Open | 827.00 |
| Bid | 816.56 x 800 |
| Ask | 822.00 x 800 |
| Day's Range | 808.90 - 833.28 |
| 52 Week Range | 668.00 - 847.50 |
| Volume | |
| Avg. Volume | 523,431 |
| Market Cap | 88.805B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 21.64 |
| EPS (TTM) | 37.80 |
| Earnings Date | Nov 02, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 907.48 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for REGN
Related Research
- Regeneron Pharmaceuticals, Inc.Analyst Report: Regeneron Phars, IncRegeneron is a biopharmaceutical company focused on treatments for eye diseases, cancer, dermatitis, and rheumatoid arthritis. Founded in 1988, Regeneron has collaborated with Amgen, Procter & Gamble, Bayer, Sanofi, and Japan's Sumitomo Chemical. The company is a component of the S&P 500, has more than 11,850 employees worldwide, and is based in Tarrytown, New York.RatingFair ValueEconomic Moat17 days agoArgus Research
Simply Wall St.Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Motley FoolStock Split Watch: Is Regeneron Pharmaceuticals Next?
Companies generally decide to engage in stock splits after their shares have soared to a level that may put them out of reach for many retail investors. A stock split doesn't change the real market value of a company, nor does it alter the value of any investor's holdings, but it does bring down the price of each individual share. Of course, it's impossible to predict which company may perform a stock split with 100% accuracy, but a top performer that has been setting new share price highs could make a good candidate.
GlobeNewswireOdronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two most common subtypes of non-Hodgkin lymphoma European Medicines Agency also reviewing odronextamab Marketing Authorization Application TARRYTOWN, N.Y., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for odronextam
